Thomasm Soloway News Today

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer

SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors TK-8001 targets a MAGE-A1 epitope

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly...

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

SAN FRANCISCO, April 08, 2022. "This is an eventful year for T-knife, filled with meaningful corporate milestones," stated Thomas M. Soloway, Chief Executive Officer of T-knife. "Today's announcement

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors